德格龙MD:利用进化和结构特征来解读蛋白质向降解,突变和对德格龙的药物反应
Haodong Xu1,2, Ruifeng Hu2,3,4, Zhongming Zhao2,5,6
1Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Molecular biology and evolution
|November 22, 2023
概括
DegronMD 识别了超过 18,000 个新的降解子,对于有针对性的蛋白质降解至关重要. 这个资源映射了影响蛋白质降解的突变,有助于癌症研究和药物发现.
科学领域:
- 生物化学和分子生物学
- 基因组学和生物信息学
- 药物发现和开发 药物发现和开发
背景情况:
- 针对蛋白质的降解是关键的治疗策略.
- E3 泛素酶和降解子调解蛋白质降解特异性和细胞平衡.
- 尽管有众多的E3结合酶,但对已识别的degron实例存在有限的知识.
研究的目的:
- 介绍DegronMD,一个开放的知识库,用于 Degron 调查.
- 描述降解子的特性及其在细胞过程中的作用.
- 确定新型降解子及其与疾病和药物反应的关联.
主要方法:
- 开发了DegronMD知识库.
- 应用模式识别和机器学习对人类蛋白质组数据.
- 使用估计的表型变化量化突变对降低功能的影响.
- 针对药物耐药性事件进行了多组合综合分析.
主要成果:
- 德格龙是进化保守的,位于翻译后修饰点附近,无序的区域和溶剂可访问的区域.
- 在人类蛋白质组中识别了超过18,000种新型降解子.
- 德格朗功能障碍与蛋白质积累和人类癌症有关.
- 产生了89,318个影响退化功能的突变的泛癌地图.
- 发现了400多种与功能性降解突变相关的耐药性事件.
结论:
- 德格龙MD提供了一个全面的资源,用于探索德格龙,它们的生物机制,以及对疾病的影响.
- 鉴定的降解和突变景观为向蛋白质降解疗法提供了新的途径.
- 德格朗MD通过突出可操作的突变和抵抗机制来促进药物发现和设计.
相关概念视频
Regulated Protein Degradation
2.5K
2.5K
The Proteasome
853
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
853
Proteins: From Genes to Degradation
12.3K
Within a biological system, the DNA encodes the RNA, and the nucleotide sequence in the RNA further defines the amino acid sequence in the protein. This is referred to as “The Central Dogma of Molecular Biology” - a term coined by Francis Crick. Central dogma is a firm principle in biology that defines the flow of genetic information within any life form. The two fundamental steps in central dogma are - transcription and translation.
Transcription is the synthesis of RNA...
Transcription is the synthesis of RNA...
12.3K
Nuclear Export of mRNA
7.7K
Before mRNAs are exported to the cytoplasm, it is crucial to check each mRNA for structural and functional integrity. Eukaryotic cells use several different mechanisms, collectively known as mRNA surveillance, to look for irregularities in mRNAs. Irregular or aberrant mRNA are rapidly degraded by various enzymes. If a defective mRNA escapes the surveillance, it would be translated into a protein which would either be non-functional or not function properly. One of the primary irregularities in...
7.7K
The Unfolded Protein Response
4.7K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.7K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K


